Gilead Sciences (GILD) Net Cash Flow (2009 - 2026)

Gilead Sciences (GILD) has reported Net Cash Flow for 18 consecutive years, with $75.0 million the latest figure, recorded in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $75.0 million, up 103.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$360.0 million (down 111.21% YoY), and the FY2025 annual result was -$2.5 billion, down 163.84% from the prior year.
• Net Cash Flow was $75.0 million for Q1 2026 at Gilead Sciences, down from $229.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $5.0 billion in Q4 2024 and troughed at -$2.9 billion in Q2 2025.
• Average Net Cash Flow over 5 years is $132.6 million, with a median of $75.0 million recorded in 2026.
• The widest YoY moves for Net Cash Flow: up 31614.29% in 2024, down 356.63% in 2024.
• Over 5 years, Net Cash Flow stood at $638.0 million in 2022, then plunged by 46.24% to $343.0 million in 2023, then soared by 1360.64% to $5.0 billion in 2024, then sank by 95.43% to $229.0 million in 2025, then slumped by 67.25% to $75.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $75.0 million in Q1 2026, $229.0 million in Q4 2025, and $2.2 billion in Q3 2025.